

Anjali Mishra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/607504/publications.pdf>

Version: 2024-02-01

26
papers

538
citations

759233

12
h-index

677142

22
g-index

26
all docs

26
docs citations

26
times ranked

1207
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2044-2050.	7.0	166
2	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. <i>Cancer Discovery</i> , 2016, 6, 986-1005.	9.4	79
3	Overview of the Use of Murine Models in Leukemia and Lymphoma Research. <i>Frontiers in Oncology</i> , 2017, 7, 22.	2.8	71
4	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3 , GATA6 , and TWIST1 in the Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2084-2092.	0.7	32
5	Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). <i>Cancer Treatment and Research</i> , 2019, 176, 83-98.	0.5	25
6	MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from SÅzary syndrome patients. <i>Leukemia Research</i> , 2017, 52, 58-66.	0.8	21
7	MicroRNAs in Cutaneous T-Cell Lymphoma: TheÅFuture of Therapy. <i>Journal of Investigative Dermatology</i> , 2019, 139, 528-534.	0.7	18
8	Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and SÅzary syndrome (SS). <i>Chinese Clinical Oncology</i> , 2019, 8, 11-11.	1.2	18
9	SÅzary Syndrome: Clinical and Biological Aspects. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 468-479.	2.3	17
10	Frequency and clinical correlates of elevated plasma EpsteinâBarr virus DNA at diagnosis in peripheral TâCell lymphomas. <i>International Journal of Cancer</i> , 2017, 140, 1899-1906.	5.1	15
11	Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). <i>Discovery Medicine</i> , 2017, 23, 189-199.	0.5	14
12	Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. <i>Expert Review of Hematology</i> , 2017, 10, 111-121.	2.2	13
13	Differential Integrin Adhesome Expression Defines Human NK Cell Residency and Developmental Stage. <i>Journal of Immunology</i> , 2021, 207, 950-965.	0.8	9
14	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 154-169.	5.0	8
15	Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2022, 12, 849917.	2.8	8
16	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S181-S190.e4.	0.4	7
17	Clinical outcomes in TâCell large granular lymphocytic leukaemia: prognostic factors and treatment response. <i>British Journal of Haematology</i> , 2021, 192, 484-493.	2.5	6
18	Cyclophosphamide Induces Durable Molecular and Clinical Responses in Patients with Relapsed T-LGL Leukemia. <i>Blood Advances</i> , 2022, , .	5.2	4

#	ARTICLE	IF	CITATIONS
19	Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?. Haematologica, 2019, 104, 864-867.	3.5	2
20	Development and Significance of Mouse Models in Lymphoma Research. Current Hematologic Malignancy Reports, 2019, 14, 119-126.	2.3	2
21	Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacidine. Blood, 2019, 134, 3776-3776.	1.4	2
22	The EZ-riding NK/T-cell lymphoma. Blood, 2019, 134, 1999-2000.	1.4	1
23	Frequency, cell lineage, and clinical correlates of lymphopenia in untreated T-cell lymphomas (TCL).. Journal of Clinical Oncology, 2017, 35, e19023-e19023.	1.6	0
24	The ETS1 Transcription Factor Is Implicated in Human and Murine Intermediate NK Cell Development Stages. Blood, 2018, 132, 2567-2567.	1.4	0
25	Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias. Blood, 2021, 138, 2449-2449.	1.4	0
26	Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. Frontiers in Oncology, 2022, 12, 858426.	2.8	0